glp-1 obesity drug news october 2025 Weight-loss drugs such as Ozempic were in the headlines a lot in – and patent protections for these drugs expire in some countries in 2026. In this edition of #PeriodicGraphics in @ Alarming rise in weight loss

By week 16, a larger proportion of AXA1125-treated subjects (3540%) than those in the placebo group (825%) reached clinically relevant thresholds for MRI-PDFF reductions of 30%, ALT reductions of 17 IU/L, and cT1 reductions of 80 ms

If concentration is moderate, switch to a higher-concentration product

Originally developed to combat obesity, this peptide is now being embraced for its multi-functional benefits , including: Enhanced fat breakdown Improved metabolism Reduced abdominal fat Support for cartilage and joint repair Accelerated recovery and healing And the best part

Cervero, F., Bennett, G

1991 Aug;32(2):143-49

The potential nephroprotective mechanisms of GLP-1RAs likely involve GLP-1RA-mediated improvements of conventional risk factors for diabetic kidney disease (control of glycaemia, postprandial lipid level, body weight and blood pressure), but perhaps also direct effects on the kidneys